Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Inclusion Criteria: * transgender male or gender diverse patient on MHT * on a stable dose of MHT for at least 3 months prior to the study * anticipate being on the same dose of MHT for the duration of the study * have steroid-related acne vulgaris as determined by the investigator with onset or worsening after initiation of MHT * have at least 20 papules or pustules on the face * consistent skin care regimen (topical and systemic medications) for at least 4 weeks prior to enrollment and continue it for the duration of the study (however, note exclusion below that topical steroids on face not allowed for 4 weeks prior to enrollment and during study)\*; * age 16 years old or older * potential participants who have ovaries and are or planning to be sexually active with partners that produce sperm will need to use a medically reliable form of birth control (including but not limited to condoms, intrauterine device, oral contraceptives) before enrollment and during the study * Note inhaled steroids are allowed as long as regimen is stable one month prior to enrollment and during the study Exclusion Criteria: * changes in topical or systemic anti-acne medications or procedures within four weeks of study enrollment * use of topical steroids on the face within 4 weeks prior to enrollment and during study * pregnant or breast-feeding patients * unable to provide informed consent, follow the protocol, attend study visits, or any other circumstance or condition which the investig…